Skip to main content


2e lijns


Phase 3, open-oabel, randomized study of amivantamab and lazertinib in combination with platinum-based chemotherapy compared with platinum-based chemotherapy in patients with EGFR-mutated locally advanced or metastatic Non- Small Cell Lung Cancer after osimertinib failure.

Contact opnemen






2e lijn na osimertinib


Erasmuc MC


Patients with EGFR-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure.


Key outcome parameters


amivantamab, lazertinib, chemotherapy

Key inclusion criteria

Inclusion criteria:

  • articipant must have histologically or cytologically confirmed, locally advanced or metastatic, non-squamous NSCLC, characterized at or after the time of locally advanced metastatic disease diagnosis by either EGFR Exon 19del or Exon 21 L858R mutation
  • Participant must have progressed on or after osimertinib monotherapy as the most recent line of treatment. Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second-line setting after prior treatment with first- or second-generation EGFR TKI.
  • Participant must have at least 1 measurable lesion, according to RECIST v1.1
  • A participant with definitively, locally treated brain metastases must be clinically stable and asymptomatic, with or without low-dose corticosteroid treatment (≤10 mg prednisone or equivalent), for at least 14 days prior to randomization.
  • ECOG 0-1

Key exclusion criteria

Exclusion criteria:

  • Participant received prior systemic anticancer therapy in the locally advanced or metastatic setting, or in the adjuvant setting, for the same nonsquamous NSCLC intended for treatment now
  • Participant received radiotherapy for palliative treatment of NSCLC less than 14 days prior to randomization
  • Participant has active brain metastases not definitively treated with local therapy
  • Participant has known small cell transformation
  • Participant has uncontrolled tumor-related pain
  • Participant has a medical history of ILD, including drug-induced ILD or radiation pneumonitis

Contact opnemen over een studie

Voor meer informatie over de studies van de afdeling long oncologie van Erasmus MC kan met onderstaande contactpersonen contact worden opgenomen.